 Antidiuretic Hormone Receptor Antagonists
"Antidiuretic Hormone Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous compounds and drugs that inhibit or block the activity of ANTIDUIRETIC HORMONE RECEPTORS.
| Descriptor ID |
D065092
|
| MeSH Number(s) |
D27.505.519.174 D27.505.696.560.311
|
| Concept/Terms |
Antidiuretic Hormone Receptor Antagonists- Antidiuretic Hormone Receptor Antagonists
- Vasopressin Antagonists
- Antagonists, Vasopressin
- Vasopressin Receptor Antagonists
- Antagonists, Vasopressin Receptor
- Receptor Antagonists, Vasopressin
- Antidiuretic Hormone Antagonists
- Antagonists, Antidiuretic Hormone
- Hormone Antagonists, Antidiuretic
|
Below are MeSH descriptors whose meaning is more general than "Antidiuretic Hormone Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Antidiuretic Hormone Receptor Antagonists".
This graph shows the total number of publications written about "Antidiuretic Hormone Receptor Antagonists" by people in this website by year, and whether "Antidiuretic Hormone Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 | | 2008 | 0 | 1 | 1 | | 2010 | 1 | 2 | 3 | | 2014 | 0 | 1 | 1 | | 2024 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antidiuretic Hormone Receptor Antagonists" by people in Profiles.
-
Nowak KL, Moretti F, Bussola N, Steele CN, Gregory AV, Kline TL, Ramanathan S, Trapletti G, Furlanello C, McCormick L, Chonchol M. Visceral Adiposity and Progression of ADPKD: A Cohort Study of Patients From the TEMPO 3:4 Trial. Am J Kidney Dis. 2024 Sep; 84(3):275-285.e1.
-
Tilley DG, Zhu W, Myers VD, Barr LA, Gao E, Li X, Song J, Carter RL, Makarewich CA, Yu D, Troupes CD, Grisanti LA, Coleman RC, Koch WJ, Houser SR, Cheung JY, Feldman AM. ?-adrenergic receptor-mediated cardiac contractility is inhibited via vasopressin type 1A-receptor-dependent signaling. Circulation. 2014 Nov 11; 130(20):1800-11.
-
Hopp K, Hommerding CJ, Wang X, Ye H, Harris PC, Torres VE. Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. J Am Soc Nephrol. 2015 Jan; 26(1):39-47.
-
Jovanovich AJ, Berl T. Where vaptans do and do not fit in the treatment of hyponatremia. Kidney Int. 2013 Apr; 83(4):563-7.
-
Lanfear DE, Sabbah HN, Goldsmith SR, Greene SJ, Ambrosy AP, Fought AJ, Kwasny MJ, Swedberg K, Yancy CW, Konstam MA, Maggioni AP, Zannad F, Gheorghiade M. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail. 2013 Jan; 6(1):47-52.
-
Borne RT, Krantz MJ. Lixivaptan for hyponatremia--the numbers game. JAMA. 2012 Dec 12; 308(22):2345-6.
-
Sarma S, Mentz RJ, Kwasny MJ, Fought AJ, Huffman M, Subacius H, Nodari S, Konstam M, Swedberg K, Maggioni AP, Zannad F, Bonow RO, Gheorghiade M. Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail. 2013 Feb; 15(2):194-202.
-
Mentz RJ, Allen BD, Kwasny MJ, Konstam MA, Udelson JE, Ambrosy AP, Fought AJ, Vaduganathan M, O'Connor CM, Zannad F, Maggioni AP, Swedberg K, Bonow RO, Gheorghiade M. Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial. Eur J Heart Fail. 2013 Jan; 15(1):61-8.
-
Dunlay SM, Gheorghiade M, Reid KJ, Allen LA, Chan PS, Hauptman PJ, Zannad F, Maggioni AP, Swedberg K, Konstam MA, Spertus JA. Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trial. Eur J Heart Fail. 2010 Apr; 12(4):367-74.
-
Belibi FA, Edelstein CL. Novel targets for the treatment of autosomal dominant polycystic kidney disease. Expert Opin Investig Drugs. 2010 Mar; 19(3):315-28.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|